EMEA (Europe, Middle East and Africa) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Report 2017

November 2017 | 116 pages | ID: E24DC5B98D7EN
QYResearch

Abstracts

In this report, the EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of B-Cell Maturation Antigen(BCMA) Targeted Therapies for these regions, from 2012 to 2022 (forecast)

• Europe: Germany, France, UK, Russia, Italy and Benelux;
• Middle East: Saudi Arabia, Israel, UAE and Iran;
• Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies market competition by top manufacturers/players, with B-Cell Maturation Antigen(BCMA) Targeted Therapies sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

• Transposagen Biopharmaceuticals
• Sutro Biopharma
• Malin Corporation
• Eureka Therapeutics
• firstVentury Equity
• Five Prime Therapeutics
• Credit Suisse Securities
• Dana-Farber Cancer Institute
• Deerfield Partners
• Onyx Pharmaceuticals
• Juno Therapeutics

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

• Bispecific Antibodies
• Antibody Drug Conjugates
• Chimeric Antigen Receptor T-Cells

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

• Liver Cancer
• Respiratory Cancer
• Brain Cancer
• Others

If you have any special requirements, please let us know and we will offer you the report as you want.

Contents

EMEA (Europe, Middle East and Africa) B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Report 2017

1 B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES OVERVIEW

1.1 Product Overview and Scope of B-Cell Maturation Antigen(BCMA) Targeted Therapies
1.2 Classification of B-Cell Maturation Antigen(BCMA) Targeted Therapies
  1.2.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Sales) Comparison by Type (2012-2022)
  1.2.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Sales) Market Share by Type (Product Category) in 2016
  1.2.3 Bispecific Antibodies
  1.2.4 Antibody Drug Conjugates
  1.2.5 Chimeric Antigen Receptor T-Cells
1.3 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Application/End Users
  1.3.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (Volume) and Market Share Comparison by Application (2012-2022
  1.3.2 Liver Cancer
  1.3.3 Respiratory Cancer
  1.3.4 Brain Cancer
  1.3.5 Others
1.4 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market by Region
  1.4.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Value) Comparison by Region (2012-2022)
  1.4.2 Europe Status and Prospect (2012-2022)
  1.4.3 Middle East Status and Prospect (2012-2022)
  1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of B-Cell Maturation Antigen(BCMA) Targeted Therapies (2012-2022)
  1.5.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2022)
  1.5.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2022)

2 EMEA B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION

2.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Competition by Players/Manufacturers
  2.1.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Market Share of Major Players (2012-2017)
  2.1.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Share by Players (2012-2017)
  2.1.3 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sale Price by Players (2012-2017)
2.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies (Volume and Value) by Type/Product Category
  2.2.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Type (2012-2017)
  2.2.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Market Share by Type (2012-2017)
  2.2.3 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sale Price by Type (2012-2017)
2.3 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies (Volume) by Application
2.4 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies (Volume and Value) by Region
  2.4.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Region (2012-2017)
  2.4.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Market Share by Region (2012-2017)
  2.4.3 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price by Region (2012-2017)

3 EUROPE B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

3.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Value (2012-2017)
  3.1.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Growth Rate (2012-2017)
  3.1.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2017)
3.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Type
3.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Application
3.4 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Value (Revenue) by Countries
  3.4.1 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume by Countries (2012-2017)
  3.4.2 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries (2012-2017)
  3.4.3 Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  3.4.4 France B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  3.4.5 UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  3.4.6 Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  3.4.7 Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  3.4.8 Benelux B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)

4 MIDDLE EAST B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION

4.1 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Value (2012-2017)
  4.1.1 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Growth Rate (2012-2017)
  4.1.2 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2017)
4.2 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Type
4.3 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Application
4.4 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Value (Revenue) by Countries
  4.4.1 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume by Countries (2012-2017)
  4.4.2 Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries (2012-2017)
  4.4.3 Saudi Arabia B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  4.4.4 Israel B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  4.4.5 UAE B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  4.4.6 Iran B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)

5 AFRICA B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION

5.1 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Value (2012-2017)
  5.1.1 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Growth Rate (2012-2017)
  5.1.2 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2017)
5.2 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Type
5.3 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Market Share by Application
5.4 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Value (Revenue) by Countries
  5.4.1 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume by Countries (2012-2017)
  5.4.2 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue by Countries (2012-2017)
  5.4.3 South Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  5.4.4 Nigeria B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  5.4.5 Egypt B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)
  5.4.6 Algeria B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate (2012-2017)

6 EMEA B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES MANUFACTURERS/PLAYERS PROFILES AND SALES DATA

6.1 Transposagen Biopharmaceuticals
  6.1.1 Company Basic Information, Manufacturing Base and Competitors
  6.1.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.1.2.1 Product A
    6.1.2.2 Product B
  6.1.3 Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.1.4 Main Business/Business Overview
6.2 Sutro Biopharma
  6.2.1 Company Basic Information, Manufacturing Base and Competitors
  6.2.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.2.2.1 Product A
    6.2.2.2 Product B
  6.2.3 Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.2.4 Main Business/Business Overview
6.3 Malin Corporation
  6.3.1 Company Basic Information, Manufacturing Base and Competitors
  6.3.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.3.2.1 Product A
    6.3.2.2 Product B
  6.3.3 Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.3.4 Main Business/Business Overview
6.4 Eureka Therapeutics
  6.4.1 Company Basic Information, Manufacturing Base and Competitors
  6.4.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.4.2.1 Product A
    6.4.2.2 Product B
  6.4.3 Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.4.4 Main Business/Business Overview
6.5 firstVentury Equity
  6.5.1 Company Basic Information, Manufacturing Base and Competitors
  6.5.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.5.2.1 Product A
    6.5.2.2 Product B
  6.5.3 firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.5.4 Main Business/Business Overview
6.6 Five Prime Therapeutics
  6.6.1 Company Basic Information, Manufacturing Base and Competitors
  6.6.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.6.2.1 Product A
    6.6.2.2 Product B
  6.6.3 Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.6.4 Main Business/Business Overview
6.7 Credit Suisse Securities
  6.7.1 Company Basic Information, Manufacturing Base and Competitors
  6.7.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.7.2.1 Product A
    6.7.2.2 Product B
  6.7.3 Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.7.4 Main Business/Business Overview
6.8 Dana-Farber Cancer Institute
  6.8.1 Company Basic Information, Manufacturing Base and Competitors
  6.8.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.8.2.1 Product A
    6.8.2.2 Product B
  6.8.3 Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.8.4 Main Business/Business Overview
6.9 Deerfield Partners
  6.9.1 Company Basic Information, Manufacturing Base and Competitors
  6.9.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.9.2.1 Product A
    6.9.2.2 Product B
  6.9.3 Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.9.4 Main Business/Business Overview
6.10 Onyx Pharmaceuticals
  6.10.1 Company Basic Information, Manufacturing Base and Competitors
  6.10.2 B-Cell Maturation Antigen(BCMA) Targeted Therapies Product Type, Application and Specification
    6.10.2.1 Product A
    6.10.2.2 Product B
  6.10.3 Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue, Price and Gross Margin (2012-2017)
  6.10.4 Main Business/Business Overview
6.11 Juno Therapeutics

7 B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES MANUFACTURING COST ANALYSIS

7.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Key Raw Materials Analysis
  7.1.1 Key Raw Materials
  7.1.2 Price Trend of Key Raw Materials
  7.1.3 Key Suppliers of Raw Materials
  7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
  7.2.1 Raw Materials
  7.2.2 Labor Cost
  7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies

8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS

8.1 B-Cell Maturation Antigen(BCMA) Targeted Therapies Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
8.4 Downstream Buyers

9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS

9.1 Marketing Channel
  9.1.1 Direct Marketing
  9.1.2 Indirect Marketing
  9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
  9.2.1 Pricing Strategy
  9.2.2 Brand Strategy
  9.2.3 Target Client
9.3 Distributors/Traders List

10 MARKET EFFECT FACTORS ANALYSIS

10.1 Technology Progress/Risk
  10.1.1 Substitutes Threat
  10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 EMEA B-CELL MATURATION ANTIGEN(BCMA) TARGETED THERAPIES MARKET FORECAST (2017-2022)

11.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Price Forecast (2017-2022)
  11.1.1 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales and Growth Rate Forecast (2017-2022)
  11.1.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate Forecast (2017-2022)
  11.1.3 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Price and Trend Forecast (2017-2022)
11.2 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Forecast by Type (2017-2022)
11.7 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Forecast by Application (2017-2022)

12 RESEARCH FINDINGS AND CONCLUSION

13 APPENDIX

13.1 Methodology/Research Approach
  13.1.1 Research Programs/Design
  13.1.2 Market Size Estimation
  13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
  13.2.1 Secondary Sources
  13.2.2 Primary Sources
13.3 Disclaimer


The report requires updating with new data and is sent in 2-3 business days after order is placed.

List Of Tables

LIST OF TABLES AND FIGURES

Figure Product Picture of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) by Type (2012-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Market Share by Type (Product Category) in 2016
Figure Bispecific Antibodies Product Picture
Figure Antibody Drug Conjugates Product Picture
Figure Chimeric Antigen Receptor T-Cells Product Picture
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) by Application (2012-2022)
Figure EMEA Sales Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Application in 2016
Figure Liver Cancer Examples
Table Key Downstream Customer in Liver Cancer
Figure Respiratory Cancer Examples
Table Key Downstream Customer in Respiratory Cancer
Figure Brain Cancer Examples
Table Key Downstream Customer in Brain Cancer
Figure Others Examples
Table Key Downstream Customer in Others
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Size (Million USD) by Region (2012-2022)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status and Forecast by Countries
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status and Forecast by Countries
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Status and Forecast by Countries
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume and Growth Rate (2012-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Major Players Product Sales Volume (K Units) (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) of Major Players (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players (2012-2017)
Figure 2016 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players
Figure 2017 B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Players
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Players (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players (2012-2017)
Table 2016 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players
Table 2017 EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Players
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sale Price (USD/Unit) by Players (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Market Share by Type (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Type (2012-2017)
Figure Sales Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Type (2012-2017)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Type (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Type (2012-2017)
Figure Revenue Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Type in 2016
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sale Price (USD/Unit) by Type (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Market Share by Application (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Application (2012-2017)
Figure Sales Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Application (2012-2017)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application in 2016
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Market Share by Region (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Share by Region (2012-2017)
Figure Sales Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Region (2012-2017)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in 2016
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Share by Region (2012-2017)
Figure Revenue Market Share of B-Cell Maturation Antigen(BCMA) Targeted Therapies by Region (2012-2017)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Regions in 2016
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Price (USD/Unit) by Region (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate (2012-2017)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Type (2012-2017)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type in 2016
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Application (2012-2017)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Application in 2016
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Countries (2012-2017)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Countries (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Countries (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Countries in 2016
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Countries (2012-2017)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries (2012-2017)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries in 2016
Figure Germany B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure France B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure UK B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Russia B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Italy B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Benelux B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Type (2012-2017)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Type (2012-2017)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Applications (2012-2017)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Market Share by Applications (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application in 2016
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) by Countries (2012-2017)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Market Share by Countries (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume Market Share by Countries in 2016
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Countries (2012-2017)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries (2012-2017)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries in 2016
Figure Saudi Arabia B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Israel B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure UAE B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Iran B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Type (2012-2017)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Type (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Type (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Type in 2016
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) by Application (2012-2017)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Application (2012-2017)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Volume (K Units) by Countries (2012-2017)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Countries (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Countries (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share by Countries in 2016
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) by Countries (2012-2017)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries (2012-2017)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share by Countries in 2016
Figure South Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Nigeria B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Egypt B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Algeria B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Table Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Transposagen Biopharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Sutro Biopharma B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Malin Corporation B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Eureka Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure firstVentury Equity B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Five Prime Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Credit Suisse Securities B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Dana-Farber Cancer Institute B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Deerfield Partners B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share in EMEA (2012-2017)
Figure Onyx Pharmaceuticals B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share in EMEA (2012-2017)
Table Juno Therapeutics B-Cell Maturation Antigen(BCMA) Targeted Therapies Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure Manufacturing Process Analysis of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Figure B-Cell Maturation Antigen(BCMA) Targeted Therapies Industrial Chain Analysis
Table Raw Materials Sources of B-Cell Maturation Antigen(BCMA) Targeted Therapies Major Manufacturers in 2016
Table Major Buyers of B-Cell Maturation Antigen(BCMA) Targeted Therapies
Table Distributors/Traders List
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) and Growth Rate Forecast (2017-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Price (USD/Unit) and Trend Forecast (2017-2022)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) Forecast by Region (2017-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share Forecast by Region (2017-2022)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Region (2017-2022)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) Forecast by Countries (2017-2022)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share Forecast by Countries (2017-2022)
Table Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) Forecast by Countries (2017-2022)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share Forecast by Countries (2017-2022)
Table Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Countries (2017-2022)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) Forecast by Countries (2017-2022)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share Forecast by Countries (2017-2022)
Table Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa B-Cell Maturation Antigen(BCMA) Targeted Therapies Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) Forecast by Type (2017-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share Forecast by Type (2017-2022)
Table EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales (K Units) Forecast by Application (2017-2022)
Figure EMEA B-Cell Maturation Antigen(BCMA) Targeted Therapies Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources